Community Research and Development Information Service - CORDIS

TRANSEURO clinical study launched, bringing new hope for cell therapy treatments for Parkinson’s disease patients

Contributed by: Dando, Weiss @ Colucci Ltd

Transeuro is a European research consortium with the principal objective of developing an efficacious and safe cellular treatment methodology for patients with early Parkinson’s disease.
The consortium consists of international experts including leading clinicians, scientists, industrial partners, ethicists and patients’ representatives who have joined forces in a new round of experimental work and fetal cell therapy trials in Parkinson's disease. The challenges of Transeuro include the step-by-step optimization of the delivery of fetal dopaminergic neurons rich grafts for patients with Parkinson's disease.

This 5 year research project is funded by the 7th Framework Programme of the European Commission, (contract number HEALTH-F5-2010-242003) . The project was launched in January 2010 and coordinated by Prof. Roger Barker from Cambridge University (UK).

Below are some of the Transeuro research highlights in the last 12 months:


TRANSEURO PROTOCOL ON TISSUE DISSECTION OF FETAL TISSUE

One of the main aims of Transeuro is to establish and test a better protocol for the preparation, storage and transplantation of brain fetal tissue containing the developing dopamine neurons that are lost in PD. The protocol has been established in collaboration with the regulatory authorities of the Transeuro clinical centers based in the UK, Sweden, Germany and France. This newly defined protocol is currently being tested by all partners. Additionally, a fetal tissue dissection database was developed to further help validate and optimize the tissue processing ahead of the clinical trial with patients.

FIRST PATIENTS ENTERED OBSERVATIONAL STUDY

Patients’ recruitment for the Transeuro observational study was launched at the beginning of 2011. Patients are being recruited in the Transeuro clinical centres located in Cambridge, Cardiff, London, Paris, Freiburg im Breisgau and Lund. The regulatory and ethical requirements necessary for this part of the Transeuro clinical program have been approved by the authorities and the recruitment is going well.

Individuals entered into the observational study, will form the cohort for the clinical transplant trial with patients being randomly selected from the former and asked if they would like to be considered for transplantation. It is expected that the first patient will be grafted with fetal VM tissue in 2012.


TRANSEURO ANNUAL MEETING

The 2nd Transeuro Annual General Meeting (AGM) was held in Bellagio, Italy on 15-18 April 2011. The meeting was held in part with the annual meeting of the Neurostemcell consortium, another FP7 funded research network which is charged with developing neuronal cells from stem cell sources for grafting in patients with Parkinson´s and Huntington´s disease. As many of the topics addressed by both consortia overlap, the holding of the two AGMs at the same location with a day of overlap allowed the participants to share scientific experience and expertise in this field and to develop new collaborations.

Contributor

Organisation

    Dando, Weiss @ Colucci Ltd
    Winterthurerstrasse 190
    8057 Zurich
    CH
    See on map

Contact

Related information

Programmes

Countries (5)

  • Austria, Germany, France, Sweden, United Kingdom
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top